These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34699264)

  • 21. Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet.
    Zhao S; Peralta RM; Avina-Ochoa N; Delgoffe GM; Kaech SM
    Semin Immunol; 2021 Feb; 52():101485. PubMed ID: 34462190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor hypermetabolism confers resistance to immunotherapy.
    Liu A; Curran MA
    Semin Cancer Biol; 2020 Oct; 65():155-163. PubMed ID: 31982512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.
    Liu X; Zhao Y; Wu X; Liu Z; Liu X
    Front Oncol; 2022; 12():931104. PubMed ID: 35924168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
    Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
    Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
    Take Y; Koizumi S; Nagahisa A
    Front Immunol; 2020; 11():324. PubMed ID: 32210957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia and the phenomenon of immune exclusion.
    Pietrobon V; Marincola FM
    J Transl Med; 2021 Jan; 19(1):9. PubMed ID: 33407613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
    Barsoumian HB; Ramapriyan R; Younes AI; Caetano MS; Menon H; Comeaux NI; Cushman TR; Schoenhals JE; Cadena AP; Reilly TP; Chen D; Masrorpour F; Li A; Hong DS; Diab A; Nguyen QN; Glitza I; Ferrarotto R; Chun SG; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
    Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
    Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
    Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.